RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Sinead Toomey; Alex J Eustace; Laura B Pritzker; Ken P H Pritzker; Joanna Fay; Anthony O'Grady; Robert Cummins; Liam Grogan; John Kennedy; Darran O'Connor; Leonie Young; Elaine W Kay; Norma O'Donovan; William M Gallagher; Roshni Kalachand; John Crown; Bryan T Hennessy

doi:10.1093/jnci/djw111

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

J Natl Cancer Inst. 2016 Jul 4;108(8):djw111. doi: 10.1093/jnci/djw111. Print 2016 Aug.

Authors

Sinead Toomey¹, Alex J Eustace², Laura B Pritzker¹, Ken P H Pritzker¹, Joanna Fay¹, Anthony O'Grady¹, Robert Cummins¹, Liam Grogan¹, John Kennedy¹, Darran O'Connor¹, Leonie Young¹, Elaine W Kay¹, Norma O'Donovan¹, William M Gallagher¹, Roshni Kalachand¹, John Crown¹, Bryan T Hennessy¹

Affiliations

¹ Medical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH).
² Medical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH). [email protected].

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Humans
Neoadjuvant Therapy*
RNA
Receptor, ErbB-2
Trastuzumab*

Substances

RNA
ERBB2 protein, human
Receptor, ErbB-2
Trastuzumab